Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Adma Biologics (ADMA) Return on Sales (2016 - 2025)

Adma Biologics (ADMA) has disclosed Return on Sales for 14 consecutive years, with 0.43% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Return on Sales fell 52.0% year-over-year to 0.43%, compared with a TTM value of 0.31% through Dec 2025, down 15.0%, and an annual FY2025 reading of 0.31%, down 15.0% over the prior year.
  • Return on Sales was 0.43% for Q4 2025 at Adma Biologics, up from 0.27% in the prior quarter.
  • Across five years, Return on Sales topped out at 0.95% in Q4 2024 and bottomed at 1.33% in Q4 2022.
  • Average Return on Sales over 5 years is 0.15%, with a median of 0.04% recorded in 2023.
  • The sharpest move saw Return on Sales soared 153bps in 2021, then tumbled -103bps in 2022.
  • Year by year, Return on Sales stood at 0.3% in 2021, then plummeted by -342bps to 1.33% in 2022, then surged by 111bps to 0.14% in 2023, then surged by 564bps to 0.95% in 2024, then tumbled by -54bps to 0.43% in 2025.
  • Business Quant data shows Return on Sales for ADMA at 0.43% in Q4 2025, 0.27% in Q3 2025, and 0.28% in Q2 2025.